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Abstract—Solid dispersion (SD) formulation has attracted much
attention due to its potential in enhancing dissolution
performances of poorly soluble active pharmaceutical ingredients 
(API). Recently, a review on dissolution performances of SDs 
classifies the improvement into 3 categories, where 82 % of the 
studies showed improved bioavailability, 8 % showed reduced 
bioavailability and 10 % revealed similar bioavailability as 
compared to pure APIs. This indicates the inconsistent degrees of 
dissolution improvement of poorly soluble APIs in SD. Although 
a few factors related to the choice of carriers have been suggested 
to contribute to the dissolution improvement, however, the 
underlying factor determining the discrepancy in the degree of 
dissolution improvement remains in vague. It is hypothesized 
that the API contributes to the degree of dissolution 
improvement of SD. Hence, the factor of amorphous solubility 
advantage of API which leads to the different degrees of 
dissolution enhancement of SD is investigated in this research. 
Polyvinylpyrrolidone vinyl acetate (PVPVA)-based SD is 
prepared with three poorly soluble APIs. Physicochemical 
properties of SD were characterized using infrared spectroscopy, 
differential scanning calorimetry (DSC) and X-ray powder 
diffraction. The dissolution efficiency of each SD was calculated 
and compared to physical mixture and pure API. Theoretical 
amorphous solubility advantage for each API was calculated 
using the thermal properties obtained from DSC. The calculated 
values were found to be correlating well with the dissolution 
enhancement of the respective SDs. Hence, this theoretical 
approach can be utilized as an initial screening tool of API 
candidates in SD formulation during early pharmaceutical 
development.
Keywords-Solid dispersion, Amorphous, PVPVA, Ketoprofen, 
Flurbiprofen, Piroxicam
I. INTRODUCTION
According to the literature, SD has shown to be a promising 
strategy in improving dissolution behaviour of poorly soluble 
drug. This in turns leads to growing interest of formulation of 
poorly soluble drug into amorphous form to increase its 
bioavailability. Theoretically, the increased dissolution rate is 
mainly ascribed to the amorphicity of the prepared drug that 
do not involve molecular bond breaking upon dissolution. The 
advantages of SD may further expedite with the use of 
hydrophilic polymer which increase wettability of a poorly
soluble drug. Even though many studies have shown the 
dissolution enhancement of SD, however, it is noticed that the 
degree of the enhancement is not straight forward. Recently, a 
thorough review on dissolution performances of solid 
dispersion by Newman et al. stated that among the published 
results, 82% of the studies (from the total of 40 investigated 
studies) shows dissolution rate enhancement after product 
being formulated into solid dispersion. Out of the 40 cases, 
8% of the study revealed deterioration of dissolution 
performance and 10% of the studies declared similar 
bioavailabilities of the SD products [1]. Furthermore, due to 
the success -led in the publication process, one should not 
exclude the possibility of the existence of under reported cases 
for the deterioration of dissolution performance of SD 
systems. More recently the limited dissolution enhancement of 
ketoprofen and naproxen despite its formulation as fully 
amorphous SD in PVP homopolymer was reported [2, 3]. 
Similarly, other researchers have also reported limited 
increment of dissolution performance of SD system [4-8]. 
The inconsistent dissolution performances lead to the poor in-
vitro/ in-vivo correlation of this type of formulation [9].
Consequently, only limited SD products are available 
commercially. The underlying factor of the inconsistent 
dissolution behaviours of the SD remains poorly understood. 
Therefore, assessment of the degree of solubility improvement 
of an amorphous drug is useful where it allows formulators to 
determine whether the solubility of amorphous form is high 
enough to justify the effort and investment in the 
manufacturing of SD at large scale [10].
To fill in the knowledge gaps on issue of dissolution 
performances of SD, PVPVA-based SD is formulated with 3 
poorly soluble APIs namely, ketoprofen, flurbiprofen and 
piroxicam by spray drying method. PVP-VA is chosen as the 
carrier in this study as it encompasses the characteristics of an 
ideal carrier which include high Tg, able to interact with the 
API, less hygroscopic, and being able to stabilize the 
amorphous form of API in solid state as well as during the 
dissolution [11-15]. Flurbiprofen and ketoprofen are 
arylpropionic acids while piroxicam is an enolic acid, 
classified as non-steroidal anti-inflammatory drugs which 
possess anti-inflammatory, analgesic, and antipyretic effects.
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They are used primarily to treat inflammation, mild-to-
moderate pain, and fever. The resultant spray dried solid 
dispersions of flurbiprofen, ketoprofen and piroxicam with 
PVPVA as its drug carrier were characterized and correlated 
to their dissolution performances correspondingly to 
investigate the use of PVPVA 6:4 copolymer in different API 
system and the difference among the dissolution performances 
of solid dispersions of 3 different poorly soluble APIs in 
relation to their amorphous solubility advantages.
.
II. MATERIAL AND METHODS
A. Materials
The polyvinylpyrrolidone-vinyl acetate copolymer,
Kollidon® VA 64 (PVPVA) was a generous gift from BASF 
distributed via ELITE ORGANIC SDN.BHD. Three model 
active pharmaceutical ingredients (APIs) namely Ketoprofen 
(KTP), Flurbiprofen (FBP) and Piroxicam (PIX) were 
purchased from AFINE Chemical LTD.
B. Solubility determination
Calibration curve for each API was constructed for known
concentration of KTP, FBP and PIX based on the λmax at
259nm, 247nm and 360nm respectively by using Beer Lambert 
plots. The API content in each sample was then measured using a 
Perkin-Elmer Lambda XLS UV/VIS spectrophotometer
(USA). λmax of KTP, FBP and PIX devoid of any 
interference from the carrier at 259nm, 247nm and 360nm 
respectively were used.
Experimental solubility of crystalline forms of the model 
APIs were measured in distilled water at room temperature. A 
saturated solution was prepared for respective API, by dissolving 
excess API powder into approximately 100mL of distilled water. 
The solution was stirred at 100 rate per minute for at least 24 
hours at room temperature. Saturated solution of the drug is then 
filtered with mixed cellulose ester microfilter of 0.45μm pore 
size (MFS membrane filter, Lot no. 41CLCA). The filtrate 
was analysed for the corresponding λmax of the
APIs.
C. Estimation of amorphous solubility advantage
It has been demonstrated that amorphous drugs can
provide higher solubility and faster dissolution rates than their 
crystalline counterparts [16]. However, solubility of 
amorphous drug is not easily measurable because of the 
tendency of rapid crystallization of amorphous solute upon 
contact with dissolution media [17, 18]. Thus, Hancock and 
Parks introduced a method for the estimation of the theoretical 
maximum solubility advantage of amorphous drugs, which 
directly reflects the driving force for their initial dissolution. 
This approach is based on calculation involving measured 
thermal properties of amorphous and crystalline forms of 
drugs from differential scanning calorimetry (DSC), including 
melting temperature, heat of fusion of the crystalline form and 
free energy difference between crystal and amorphous forms. 
From these properties, the amorphous solubility advantage
was predicted as a function of temperature using a simple 
thermodynamic calculation [19]. The solubility advantage of 
amorphous pharmaceuticals is reflected by solubility ratio of 
the amorphous to crystalline form, which is calculated by (1),
(1)
where σamorph/σcrystal is the ratio of the solubility of the
amorphous form to the solubility of crystalline form of API, 
which could be obtained from the experimental value in 
section II, B. ΔG is the free energy difference between 
the amorphous and crystalline form, R is the universal gas 
constant and T is the temperature in Kelvin [16]. The free 
energy difference between amorphous and crystalline 
counterparts, ΔG is obtained from the (2), i.e. Hoffman
equation,
(2)
where T is the operating temperature, ΔHf is the enthalpy 
of fusion, Tm is the melting temperature, respectively which 
could be obtained by scanning the pure API using DSC and 
ΔT is Tm minus T. The trend of amorphous solubility
advantage calculated in this section will then be compared to 
the dissolution performances of the prepared ASD system with 
the intention to unfold the underlying factor that lead to the 
different degrees of dissolution enhancement of SD in 
comparison to their PM systems, as observed among the 
literature.
D. Preparation of physical mixture and solid dispersion
Physical mixture (PM) of APIs (KTP, FBP, PIX) and
PVPVA were prepared by gentle mixing of total 1g of 
weighed powders (30%w/w API in PVPVA) using a mortar 
and pestle for approximately 2 minutes.
Meanwhile, spray drying method is used for the production 
of SD in this study. A total of 5.0g of API and PVPVA 
mixtures in 30% API loading were prepared using 50% v/v 
ethanol in water. The spray-dried SD products were prepared 
using a Buchi mini-spray dryer B-290, with operating 
parameters set 60°C; for the corresponding systems shown in 
Table I. The yield obtained was approximately 25-30%.
TABLE I. PARAMETERS USED IN THE PREPARATION OF PVPVA-BASED
SD SYSTEMS
Systems
Spray dry processing parameters
inlet outlet
Feeding
rate
SD 30% KTP PVPVA 80 60 5
SD 30% FBP PVPVA 80 60 5
SD 30% PIX PVPVA 90 75 5
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E. Physical characterization of spray dried solid dispersion
a. Solid state characterization
Solid state characterization of the prepared solid dispersions 
and PM of API/PVPVA were carried out by scanning in 
differential scanning calorimetry (DSC), attenuated total 
reflectance- fourier transform infrared (ATR-FTIR) 
spectroscopy and X-ray powder diffraction (XRPD).
DSC measurements were performed with PerkinElmer 
Pyris 6 DSC. Approximately 2-4mg of samples was packed in 
crimped aluminium pan and heated under dry nitrogen purge. 
KTP and FBP samples were heated from -20°C to 200°C at 
10°C/min, whereas PIX samples were heated from 0°C to 
300°C. The results were analyzed using Pyris Data Analysis.
Attenuate Total Reflectance – Fourier Transform Infrared 
(ATR-FTIR) spectra of the raw, PM and SD samples were 
recorded over a wavenumber range of 500 cm-1 to 4000 cm-1 
with a resolution of 4cm-1 and 32 scans using Thermo Nicolet 
FTIR Nexus spectrometer coupled with ATR accessory. The 
spectra were analysed using OMNIC software.
XRPD analysis of raw materials, PMs and SDs were 
performed with an XRPD, Bruker D8 Advance equipped with 
a copper X-ray Tube (1.54060 Å). Samples were pressed into 
a sample holder to generate a flat and smooth plane surface. 
The samples were then exposed to an X-ray beam with voltage 
of 40 kV and a current 40 mA. All measurements were 
performed from 3o to 50o (2θ) coupled with scanning
speed of 0.02o / step and 1 second for every scan step to
cover the characteristic peaks of the crystalline API.
b. Dissolution studies
Dissolution tests for PM and SD of API-PVPVA were 
performed using paddle method in a calibrated Varian VK7000 
Dissolution Apparatus. 900mL of distilled water was used as a 
dissolution medium. The dissolution medium was set at 37.0 ± 
0.5°C and the paddle speed of 50 rpm was used. Pure APIs, 
PVPVA, PM and SD products which were sieved to a controlled 
particle size range of 100-106 μm were added to the
dissolution medium at the beginning of dissolution experiment. 
10ml of the samples was withdrawn at 2, 5, 10, 15, 20, 30, 40, 50, 
60 and 120 minutes. The volume of dissolution medium 
withdrawn was immediately replaced by introducing the same 
volume of fresh medium into the dissolution vessel. The samples 
were then filtered with mixed cellulose ester
microfilter of 0.45μm pore size (MFS membrane filter, Lot no.
41CLCA) and analyzed for content of APIs using UV-vis 
spectroscopy at their respective λmax. Dissolution 
performances of all the prepared SD were compared using 
dissolution efficiency (DE). DE is expressed as the area under 
the dissolution curve between time points t1 and t2 divided by 
the area under the curve at 100% dissolution, y100, over the 
same time period. DE was measured using the trapezoidal 
method, where the area under the curve is the sum of all the 
trapeziums defined by (3),
(3)
where ti is the ith time point, yi is the percentage of dissolved 
product at time ti [20]. Subsequently, percentage of DE (%) 
was calculated using (4) as below,
(4)
where y is the percentage of drug release (Khalid, 2015).
III. RESULT AND DISCUSSION
A. Theoretical estimation of amorphous solubility advantage
ratio of the tested drug
Amorphous solubility advantage is reflected by the free 
energy difference between the amorphous API and crystalline 
counterparts, which was calculated according to (1) and (2) as 
described in section II, C [16], based on the thermal 
properties of API measured by DSC in section II, B. Table II 
illustrates the melting temperature, melting enthalpy, free 
energy difference between the amorphous form and crystalline 
form, experimental solubility and calculated solubility ratio of 
crystalline form amorphous forms and theoretical amorphous 
solubility of different APIs.
As shown in column 4 of Table II, PIX has the highest free 
energy difference between its amorphous and crystalline state. 
This is followed by FBP and KTP. This trend is in parallel to 
the predicted solubility ratio of amorphous API to crystalline 
API of the APIs as shown in column 6 of Table II.
TABLE II.     M ELTING TEMPERATURE OF THE CRYSTALLINE APIS, MELTING ENTHALPY OF THE CRYSTALLINE APIS, FREE ENERGY DIFFERENCE BETWEEN THE
CRYSTALLINE APIS AND THEIR AMORPHOUS FORM, EXPERIMENTAL SOLUBILITY OF THE CRYSTALLINE APIS, SOLUBILITY RATIO AND THEORETICAL SOLUBILITY OF 
AMORPHOUS APIS
Drug- Melting Melting enthalpy Free energy difference, ΔG, Experimental Solubility Theoretical amorphous
PVPVA Temperature (K) ΔH (KJ/mole) (KJ/mole) Solubility (mg/mL) ratio solubility (mg/L)
KTP 366.32 32.46 4.21 0.148 5.13 0.7575
FBP 386.03 30.47 4.81 0.027 6.46 0.1744
PIX 470.95 38.18 8.59 0.040 27.93 1.1193
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B.  Solid state characterization patterns were shown in the diffractograms of SD 30% KTP and
FBP  in  PVPVA,  respectively  (Figure  2  (G)  and  (H)
Figure  1  presents  DSC  thermograms of  the  freshly respectively). These results are in agreement to the deduction
obtained from DSC (absence of any melting endothermic peak)
prepared SD 30% APIs-PVPVA systems. which concludes that the SD 30%w/w KTP and FBP in
PVPVA are amorphous in nature.
In contrast, characteristic peaks of the PIX in the region of
8
o
to 30
o
are detected in SD 30% PIX in PVPVA in lower
diffracting  intensities  (Figure  2  (I)).  This  ascertains  the
presence of crystalline traces of PIX in the SD PIX PVPVA
sample. Area under the diffracted peaks was calculated using
ORIGIN 8.0 software. The obtained area revealed that the
percentage of PIX crystallinity was less than 10%. Besides,
doublet diffraction peaks were seen in the region of 8
o
which
suggests the presence of different polymorph forms of PIX, i.e.
Form II. Once again, this result is in agreement to the result
deduced from ATR-FTIR finding (presence of Form II crystal
as indicated by OH absorption peak at 3392cm
-1
) and DSC
finding (presence of melting endothermic peak).
Figure 1. DSC thermograms of first heating cycle of (A) SD 30%w/w KTP 
PVPVA (B) SD 30%w/w FBP PVPVA (C) SD 30%w/w PIX PVPVA and (D)
PVPVA.
The absence of any melting endothermic peak indicates the 
amorphous nature of SD products of KTP and FBP (Figure 1
(A) and Figure 1 (B)). Besides a Tg detected at circa 94.36 
o
C, 
SD 30 PIX-PVPVA also shows a melting endotherm at circa 
168.93°C due to its partly crystalline property (Figure 1 (C)). 
This suggests the combination of amorphous and crystalline 
components present in SD PIX PVPVA system. Generally, the
presence of crystalline traces of  PIX in  the SD  PIX
PVPVA  is  predicted   to interfere the dissolution
Amorphicity of the spray dried samples could be further 
confirmed via scanning in X-ray powder diffraction. Figure 2 
shows the XRPD diffractograms of all the pure APIs and their 
corresponding physical mixture and spray dried samples.
All the tested drugs in this study show certain degree of drug 
polymer interaction through hydrogen bonding (data not shown). 
This may contribute to the better physical stabilization of the 
solid dispersion upon storage. The extent of hydrogen bond 
interaction between the APIs and PVPVA6:4 is reflected by the 
extent of C=O downshift. This is because weakening of vibration 
energy of C=O stretching after bonding to the hydrogen acceptor 
from API, causing the redshift to the lower wavenumber [2, 21]. 
Examining extend of C=O shift from PVPVA, estimation of the 
drug-polymer interaction is in the following trend i.e. KTP-PVP > 
PIX-PVPVA > FBP-PVPVA. However, due to the interference of 
several peaks in the region of C=O for the FBP system in this 
study, the suggested trend may only be treated as gross 
estimation.
The diffractograms showed the characteristic diffracted 
peak of all APIs (KTP, FBP, PIX) in the region of 3
o
to 30
o
(Figure 2 (A) to (C)). These peaks were also noted in all the 
physical mixtures which indicate the presence of crystalline 
APIs in those samples (Figure 2 (D) to (F)). However, halo
Figure 2.  X-ray diffractograms of the investigated samples, (A) KTP, (B) 
FBP, (C) PIX, (D) PM 30%w/w KTP PVPVA, (E) PM 30%w/w FBP 
PVPVA, (F) PM 30%w/w PIX PVPVA, (G) SD 30%w/w KTP PVPVA, (H) 
SD 30%w/w FBP PVPVA, (I) SD 30%w/w PIX PVPVA and (J) PVPVA
C. Dissolution performances of solid dispersion and physical 
mixture
The ability of amorphous SD in producing formulations 
with enhanced dissolution rate and bioavailability was widely 
reported [2, 22-25]. This is due to the ability of amorphous 
system in exhibiting high level of supersaturation and thus 
higher apparent solubility than its crystalline counterpart [1]. 
After the basic characterization of the prepared SD APIs-
PVPVA system, the dissolution performances of SD systems 
were compared to their corresponding pure API and PM 
systems in order to assess the advantages in dissolution 
performance of SD system. Figure 3 displays the dissolution 
profiles of the 3 different APIs in their pure powder form, 
PMs and SD systems.
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Figure 3.  Comparison of dissolution profile among SD systems (A) KTP PVPVA system, (B) FBP PVPVA system and (C) PIX PVPVA system
Figure 3 demonstrated the dissolution rate of amorphous 
PM API-PVPVA systems (symbol “Δ”), which show a 
higher initial release rate than their corresponding API 
systems (symbol “o”) consistently, except PIX. The increase 
the dissolution rate of the PM in comparison to the API may 
be due to the wetting effect of the hydrophilic carrier [25, 26]. 
Besides, Figure 3 also demonstrated the dissolution rate of 
amorphous SD API-PVPVA systems (symbol “□”), which
show a higher overall release rate than their corresponding PM 
API-PVPVA systems consistently.
SD KTP PVPVA system showed an equal dissolution rate as 
its PM system initially, followed by a slightly higher dissolution 
rate than its PM system (Figure 3 (A)). In FBP system (Figure 3 
(B)), the initial dissolution rate of SD system is lower than the 
PM system, subsequently, the percentage of drug release of SD 
system was significantly higher than its PM system. Due to 
inconsistent degree of increment in drug release rate of SD 
system as compared to its PM system over the time period of 
dissolution, the dissolution profile is quantitatively analysed by 
using dissolution efficiency that has been described in section II, 
E, b. Table III displays the percentage of dissolution efficiency of 
the APIs, PMs, SDs systems and the degree of dissolution rate 
improvement in the dissolution performance of SD system as 
compared to the corresponding PM system. From the observation 
of Figure 3 and Table III, the rank order of the increased 
percentage of drug release of API in
SD system in comparison to their PM system, i.e. PIX > FBP > 
KTP was found to follow the exact trend seen in solubility 
advantage ratio of APIs as calculated in section III, A, Table II.
TABLE III. PERCENTAGE OF DISSOLUTION EFFICIENCY OF PURE API, PM
API PVPVA AND SD API PVPVA
Systems
Dissolution efficiency (DE%)
KTP FBP PIX
Drug alone 76.72 43.20 29.20
PM 67.58 51.03 29.02
SD 99.51 78.95 79.31
Dissolution efficiency
32.08 35.36 63.41improvement of SD (%)
In the current study, dissolution efficiency results 
demonstrated that amorphous solid dispersion (ASD) can provide 
higher solution concentration than the crystalline PM system, 
which is in concordance with the expectation stated in Hancock 
and Parks [19] whereby amorphous state of an API contributes to 
the dissolution enhancement of poorly soluble system. However, 
different APIs used in this study exhibited different degree of 
dissolution rate increment despite similar drug loading, same 
carrier and method of preparation used. For instance, even though 
fully amorphous system of the SD KTP
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PVPVA system was obtained, the degree of dissolution 
enhancement was limited as compared to the partially 
amorphous system as shown by the SD PIX PVPVA system 
which reveals dramatic dissolution rate increment in 
comparison to its PM system. This result has suggested that 
the presence of crystalline trace in a SD system may not be the 
main reason for the deterioration of dissolution performance 
of a crystalline SD system, as suggested in most of the 
published papers [22, 27].
Drug-polymer interaction has been suggested to be 
important in physical stabilization upon storage as well as 
dissolution [28, 29]. Likewise, some studies suggested that 
drug polymer interaction plays a significant role in 
precipitation inhibition and amorphous stabilization during 
dissolution process [1, 30]. However, in this study, 
dissolution performance of the ASD was the highest in PIX-
PVPVA, i.e. approximately 2 folds increase in dissolution 
efficiency as compared to KTP and FBP SD systems. These 
results were not following the gross estimation trend of drug-
polymer interaction. Therefore, in the current study, there is 
no clear relationship between the drug-polymer interactions to 
the degree of dissolution enhancement of SD system.
During dissolution, dissolution rate of solid is proportional to 
the surface area of solid and the difference between the 
concentration of the saturated solution surrounding the solid 
and the concentration in the bulk of solvent, as described by 
the Noyes and Whitney equation [31]. Upon achieving a 
constant release rate at the dissolving front, the solution at the 
saturated dissolving front would be equivalent to the solubility 
of the API. Thus, the higher solubility advantage of an 
amorphous API could drive its dissolution process, assuming 
other parameters that affect the dissolution process, i.e. surface 
area of API are kept constant [2]. Thus, the expected 
solubility improvement of amorphous form would be the 
highest in PIX, followed by FBP > KTP.
The solubility advantage of amorphous to crystalline state 
of the 3 APIs was found to correlate well to the extent of 
dissolution efficiency enhancement of the SD systems as 
compared to its PM systems of APIs, i.e. SD PIX -PVPVA > 
SD FBP-PVPVA > SD KTP-PVPVA, as presented by Table 2 
and Table 3. This suggests that the dissolution performance of 
a SD API-PVPVA system is API-specific where the free 
energy difference between the amorphous and crystalline form 
largely dictate the overall dissolution performance of a spray-
dried ASD system. However it is worth emphasizing that there 
were visible white particles in the midst of the dissolution 
vessel during the dissolution processes which settled down at 
the bottom of the vessel. Similar observations have been 
reported in other researches during dissolution process [32,
33]. Therefore, it is believed that the degree of dissolution 
enhancement of the ASD has been compromised due to the 
dramatic decrease of surface area as a result of extensive 
agglomeration. API with a higher amorphous solubility 
advantage may afford the phenomenon of agglomeration 
which sustains its amorphous advantages in the SD 
formulation during the dissolution process.
Hence, coupling the knowledge of amorphous solubility 
advantage in the preparation of SD formulation, one may
estimate if a candidate of API is suitable to be formulated as 
SD system by taking the compromising factor of 
agglomeration into consideration. With that, API with a high 
ratio of amorphous solubility advantage is preferred to be 
formulated as an ASD.
IV. CONCLUSION
Fully amorphous PVPVA-based SD systems have been 
successfully produced for the prepared SD FBP and KTP 
systems. On contrary, SD PIX PVPVA shows partially 
amorphous system with crystalline trace. Instead of viewing 
the presence of crystalline trace as undesirable characteristic, 
sample with crystalline traces in SD PIX PVPVA system have 
been found to have the highest dissolution efficiency among 
the tested systems.
Although it has been postulated that drug-polymer 
interaction contributes to dissolution improvement of SD, 
however, to the best of our knowledge, no research has 
successfully established a relationship between drug-polymer 
interactions with the degree of dissolution improvement. 
Similarly in this study, all the system shows certain degree of 
drug-polymer interaction, but no clear relationship could be 
concluded for the observed different degree of dissolution rate 
increment. With that, more studies should be focused on 
investigating the relationship between strength of drug-
polymer interaction and the degree of dissolution 
improvement in SD formulation.
Theoretical approach suggested in this research for the use 
of future screening of API has shown to be correlated well to 
the degree of dissolution enhancement of SD. Even though 
there are only three systems tested in the current study, the use 
of this approach is worth for further investigation of other 
API-polymer systems. The benefit of this approach is laid in 
its simplicity where only the simple thermal property of the 
drug is required. This approach will enable early screening on 
the suitability of a newly identified compound to be 
formulated as an amorphous solid dispersion.
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